Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Syndax Pharmaceuticals is actively advancing innovative cancer therapies and will present at the upcoming J.P. Morgan Healthcare Conference, highlighting its commitment to cancer care and the potential of its pipeline [1][3]. Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3]. - The company's pipeline includes Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3]. - Syndax is conducting several clinical trials to explore the full potential of its pipeline [3]. Event Details - Michael A. Metzger, the CEO of Syndax Pharmaceuticals, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 3:00 p.m. PT / 6:00 p.m. ET [1]. - A live webcast of the presentation will be available on the company's website, along with a replay for a limited time [2].